Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Centrexion Therapeutics Corp.

centrexion.com

Latest From Centrexion Therapeutics Corp.

Pain/Addiction Products Need Regulatory Streamlining To Incentivize Development, Sponsors Say

Industry speakers offer series of suggestions for ways to incentivize development of pain and addiction products at US FDA public meeting on the opioid crisis.

Review Pathway Research & Development

Finance Watch: Two New IPOs – IGM In the US, Henlius In Hong Kong – Gross Nearly $600m

Public Company Edition: IGM raised $175m to advance its IgM antibodies and Henlius brought in $410m for its novel drug and biosimilar platforms. Also, Acadia follow-on brings in $250m, PTC sells $350m worth of stock and debt, and Karyopharm royalty deal totals $150m.

Financing Business Strategies

Deal Watch: Lilly Takes Global Rights To Centrexion Non-Opioid Pain Candidate

Lilly licenses non-opioid pain candidate from Centrexion. China’s Hansoh gets rights to inibelizumab from AstraZeneca spinout Viela for lead indication neuromyelitis optica as well as other autoimmune and blood cancer indications.

Deals Business Strategies

Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets

Not every drug developer can go public, but biopharma IPOs are launching in multiple markets, including Moderna's prospective $500m US offering and Innovent's $421m Hong Kong IPO. Also, Sarepta prices a $500m FOPO and Omeros sells $210m in notes.

Financing Asia Pacific
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Centrexion Therapeutics Corp.
  • Senior Management
  • Jeffrey B Kindler, CEO
    Nick Harvey, CFO
    James N Campbell, MD, Pres. & CSO
    Randall Stevens, MD, CMO
    Kerrie Brady, EVP, Corp. Strat. & CBO
  • Contact Info
  • Centrexion Therapeutics Corp.
    Phone: (617) 837-6911
    200 State St.
    6th Fl.
    Boston, MA 02109
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register